Blood Cancer Clinical Trials | Leukemia & Lymphoma Clinical Research

Connect® MDS/AML Disease Registry

Status: Enrolling, Phase
Updated: 12/31/1969

INTEGRIS Cancer Institute Southwest Medical Center

from

Oklahoma City, OK

Connect® MDS/AML Disease Registry

Status: Enrolling, Phase
Updated: 12/31/1969

Mercy Cancer - St. Louis

from

Saint Louis, MO

Connect® MDS/AML Disease Registry

Status: Enrolling, Phase
Updated: 12/31/1969

Ccs Oncology

from

Williamsville, NY

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Status: Enrolling, Phase II
Updated: 12/31/1969

Foothills Hospital

from

Calgary,

Florida Cancer Specialists North Region Sarah Cannon Research

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Saint Petersburg, FL

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Bonita Springs, FL

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Hackensack, NJ

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Hudson, FL

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Naples, FL

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

from

New Brunswick, NJ

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

from

New Port Richey, FL

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

from

New York, NY

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Status: Enrolling, Phase III
Updated: 12/31/1969

Hematology, Oncology, Reproductive Clinical Trial

from

Sarasota, FL

A Study of TAS-120 in Patients With Advanced Solid Tumors

Status: Enrolling, Phase I, II
Updated: 12/31/1969

UCSF - Helen Diller

from

San Francisco, CA

B Acute Lymphoblastic Leukemia Clinical Trial

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Status: Enrolling, Phase III
Updated: 12/31/1969

West Virginia University Charleston Division

from

Charleston, WV

B Acute Lymphoblastic Leukemia Clinical Trial

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Status: Enrolling, Phase III
Updated: 12/31/1969

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

from

New York, NY

B Acute Lymphoblastic Leukemia Clinical Trial

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Status: Enrolling, Phase III
Updated: 12/31/1969

Princess Margaret Hospital for Children

from

Perth,

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Saint Vincent Hospital Cancer Center Green Bay

from

Green Bay, WI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Yale-New Haven Shoreline Medical Center

from

Guilford, CT

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Essentia Health Hibbing Clinic

from

Hibbing, MN

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Hawaii Oncology Inc-POB I

from

Honolulu, HI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Essentia Health - Jamestown Clinic

from

Jamestown, ND

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Good Samaritan Medical Center

from

Lafayette, CO

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Desert West Surgery

from

Las Vegas, NV

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Michigan Breast Specialists-Macomb Township

from

Macomb, MI

Great Lakes Cancer Management Specialists-Macomb Medical Campus

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Macomb, MI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Fairview Maple Grove Medical Center

from

Maple Grove, MN

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Camden Clark Medical Center

from

Parkersburg, WV

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Kaiser Permanente Washington

from

Seattle, WA

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

PeaceHealth United General Medical Center

from

Sedro-Woolley, WA

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Southwest Illinois Health Services LLP

from

Swansea, IL

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Saint Joseph Health System-Tawas City

from

Tawas City, MI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Essentia Health Virginia Clinic

from

Virginia, MN

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Michigan Breast Specialists-Warren

from

Warren, MI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Advanced Breast Care Center PLLC

from

Warren, MI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Sanford Cancer Center Worthington

from

Worthington, MN

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Wellspan Health - York Cancer Center

from

York, PA

Chronic Myelogenous Leukemia Clinical Trial

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Status: Enrolling, Phase II
Updated: 12/31/1969

University of Chicago Dept. of Oncology

from

Chicago, IL

Chronic Myelogenous Leukemia Clinical Trial

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Status: Enrolling, Phase II
Updated: 12/31/1969

Sarah Cannon Research Institute Sarah Cannon Research

from

Nashville, TN

Chronic Myelogenous Leukemia Clinical Trial

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan Kettering SC

from

New York, NY

Louisville Oncology Suburban - Norton Cancer Institute

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Louisville, KY

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Status: Enrolling, Phase
Updated: 12/31/1969

Local Institute

from

Toronto,

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

McFarland Clinic PC - Ames

from

Ames, IA

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Duluth Clinic Ashland

from

Ashland, WI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Central Care Cancer Center - Bolivar

from

Bolivar, MO

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

IHA Hematology Oncology Consultants-Brighton

from

Brighton, MI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Saint Alphonsus Cancer Care Center-Caldwell

from

Caldwell, ID

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Hematology Oncology Consultants-Clarkston

from

Clarkston, MI

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Essentia Health - Deer River Clinic

from

Deer River, MN

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Status: Enrolling, Phase III
Updated: 12/31/1969

Marshfield Clinic Cancer Center - Eau Claire

from

Eau Claire, WI

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Status: Enrolling, Phase II
Updated: 12/31/1969

McFarland Clinic PC - Ames

from

Ames, IA

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Status: Enrolling, Phase II
Updated: 12/31/1969

Central Care Cancer Center - Bolivar

from

Bolivar, MO

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Vincent Hospital Cancer Center Green Bay

from

Green Bay, WI

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Status: Enrolling, Phase II
Updated: 12/31/1969

Vidant Oncology-Richlands

from

Richlands, NC

Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS

Status: Enrolling, Phase I
Updated: 9/12/2017

Institut Paoli-Calmettes

from

Marseille,

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Status: Enrolling, Phase I, II
Updated: 12/31/1969

University of Alberta Hospital

from

Edmonton,

Lymphocytic Leukemia, Chronic Clinical Trial

A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase I
Updated: 1/12/2015

from

La Jolla, CA

Lymphocytic Leukemia, Chronic Clinical Trial

A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase I
Updated: 1/12/2015

from

Nashville, TN

Lymphocytic Leukemia, Chronic Clinical Trial

A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase I
Updated: 1/12/2015

Acute Promyelocytic Leukemia With PML-RARA Clinical Trial

from

Springfield, OR

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Status: Enrolling, Phase III
Updated: 12/31/1969

Sanford Broadway Medical Center

from

Fargo, ND

Myeloid Leukemia, Chronic, Chronic Phase Clinical Trial

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Sloan-Kettering Cancer Center - New York

from

New York, NY

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Baltimore, MD

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Boston, MA

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Denver, CO

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Hackensack, NJ

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Hershey, PA

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Houston, TX

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

Little Rock, AR

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Status: Enrolling, Phase
Updated: 12/31/1969

from

New Brunswick, NJ

A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Status: Enrolling, Phase I
Updated: 12/31/1969

Memorial Sloan Kettering Bergen

from

Montvale, NJ

A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Status: Enrolling, Phase I
Updated: 12/31/1969

Washington University; Wash Uni. Sch. Of Med

from

Saint Louis, MO

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

Status: Enrolling, Phase I
Updated: 12/31/1969

Alberta Children's Hospital

from

Calgary,

Relapsed/Refractory AML Clinical Trial

A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Duarte, CA

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

West Virginia University Charleston Division

from

Charleston, WV

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Sanford Broadway Medical Center

from

Fargo, ND

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

from

New York, NY

Chronic Lymphocytic Leukemia Clinical Trial

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status: Enrolling, Phase I
Updated: 12/31/1969

University of Rochester Wilmot Cancer Inst.

from

Rochester, NY

Acute Lymphoblastic Leukemia Clinical Trial

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Status: Enrolling, Phase I, II
Updated: 12/31/1969

St. Jude Affiliate-Charlotte

from

Charlotte, NC

Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Status: Enrolling, Phase I
Updated: 12/31/1969

University of Colorado Cancer Center

from

Denver, CO

Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Status: Enrolling, Phase I
Updated: 12/31/1969

Mount Sinai Hosp

from

New York, NY

Immunology / Infectious Diseases, Oncology Clinical Trial

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Status: Enrolling, Phase III
Updated: 12/31/1969

St. Vincents Hospital Sydney

from

Darlinghurst,

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Status: Enrolling, Phase I
Updated: 12/31/1969

Inova Melanoma and Skin Cancer Center / Inova Schar Cancer Institute

from

Fairfax, VA

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

Central Cancer Care Center

from

Bolivar, MO

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

Rocky Mountain Cancer Centers, LLP- Boulder

from

Boulder, CO

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

Pontchartrain Cancer Center

from

Covington, LA

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

HSHS St. Vincent Hospital Regional Cancer Center

from

Green Bay, WI

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

Raab Clinic

from

Morehead City, NC

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

MHO Research Foundation, Inc.

from

New York, NY

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

Rocky Mountain Cancer Centers, LLP- Parker

from

Parker, CO

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

Compass Oncology- Barnes

from

Portland, OR

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Status: Enrolling, Phase
Updated: 12/31/1969

Gregory Smith, MD (Private Practice)

from

Saint Helena, CA

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Status: Enrolling, Phase III
Updated: 12/31/1969

Mount Sinai School of Medicine

from

New York, NY

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Albany, NY

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Bethlehem, PA

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Charleston, SC

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Joliet, IL

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Lake Success, NY

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Philadelphia, PA

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017

from

Santa Rosa, CA

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Status: Enrolling, Phase III
Updated: 5/31/2017